Results 21 to 30 of about 70 (39)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

EClinicalMedicine, 2020
Fahrettin Covut, Tariq Kewan, Mohammed J Al-Jaghbeer   +2 more
exaly  

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Lancet, The, 2021
Thomas Shanahan, Christy Burden, Tim Felton   +2 more
exaly  

Evaluation of tocilizumab for intractable Takayasu arteritis and 18F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment

Journal of Cardiology, 2021
Yasuhiro Maejima, Mike Saji
exaly  

Tocilizumab in isolated polymyalgia rheumatica: A systematic literature review

Seminars in Arthritis and Rheumatism, 2020
Mitsuhiro Akiyama, Tsutomu Takeuchi, Yuko Kaneko   +2 more
exaly  

Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review

Multiple Sclerosis and Related Disorders, 2021
William Hoffman, Paul Elsbernd, Dean Wingerchuk   +2 more
exaly  

Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients

Journal of Autoimmunity, 2018
Carlo Salvarani, Isabelle Koné-Paut, Christian Lavigne   +2 more
exaly  

Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease

International Immunopharmacology, 2020
Shahnam Sedigh Maroufi, Hamidreza Samaee, Shahram Ala   +2 more
exaly  

Outcome of tocilizumab treatment in refractory ocular inflammatory diseases

Acta Ophthalmologica, 2016
Sukhum Silpa-Archa
exaly  

Tocilizumab

Reactions Weekly, 2017
openaire   +2 more sources

Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti–IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease

Blood, 2008
Takagi Nobuhiro, Nishimoto Norihiro
exaly